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Transient dephosphorylation of FAK at Tyr-397 is required for cell cycle withdrawal early on during
myogenesis. Here, we show that upon serum starvation of C2C12 myoblasts, FAK is transiently
dephosphorylated in parallel with SHP-2 activation and association with FAK. SHP-2 knockdown
by RNA interference suppressed the transient upregulation of SHP-2 and dephosphorylation of
FAK during myogenesis. Furthermore, depletion of SHP-2 retarded the cell cycle withdrawal and
the differentiation of serum-starved myoblasts into myotubes. These data provide a mechanistic
basis for the reduction in FAK activity in differentiating myoblasts, indicating that myogenesis is
critically triggered by FAK/SHP-2 complex.
Structured summary:
MINT-7258938: Fak1 (uniprotkb:P34152) physically interacts (MI:0915) with shp2 (uniprotkb:P35235) by
anti bait coimmunoprecipitation (MI:0006)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Myogenesis is a highly ordered process that comprises cell cycle
withdrawal and differentiation of myoblasts into myotubes. This
process is coordinately regulated by activation of muscle-speciﬁc
helix-loop-helix transcription factors such as Myf-5, MyoD, Myog-
enin and MRF-4, collectively known as muscle regulatory factors
(MRFs) [1]. The activation of MRFs requires signals mediated by
growth factors, but cell–extracellular matrix (ECM) adhesion is
also essential for normal myogenesis [2–4].
Cells interact with ECM via a variety of receptors, the integrins
being the most common [3,5]. Integrin-mediated signaling in-
volves downstream activation of many molecules, but focal adhe-
sion kinase (FAK) is particularly critical for signals arising from
cell adhesion to ECM [6]. Binding of integrins to ECM ligands in-
duces FAK phosphorylation at Tyr-397, which is a hallmark of its
activation [7]. Phosphorylated FAK modulates cell proliferation,
survival and differentiation [8]. In myoblasts, upregulation of FAK
phosphorylation promotes proliferation, but it is also important
for differentiation into myotubes [9–11]. Phosphorylated FAK
stimulates myoblasts to remain proliferating by a mechanism
related to activation of cyclin-dependent kinases and cyclins [9].chemical Societies. Published by E
édica, Faculdade de Ciências
Universitária ‘‘Zefferino Vaz”,
51.
ini).Consistent with this, transient dephosphorylation of FAK at Tyr-
397 is required for the exit of cell cycle during myogenesis [9].
Aside from being upregulated by adhesion-dependent mechanisms
and growth factors, the cellular levels of phosphorylated FAK also
depends on a negative regulation by protein–tyrosine phospha-
tases [7]. SHP-2 (SH2 domain-containing protein–tyrosine
phosphatase) plays an essential role in regulating FAK phosphory-
lation and signaling in many cell types [7,8,12–15]. Interestingly,
SHP-2 positively regulates myogenesis by promoting differentia-
tion of myoblasts via a pathway dependent on activation of RhoA
[16–18]. However, it is yet unknown whether SHP-2 is involved
in the modulation of FAK phosphorylation during myogenesis.
Here, we present direct evidence in support of a critical role for
SHP-2 in regulating FAK phosphorylation and myogenesis is re-
sponse to serum starvation in C2C12 myoblasts.2. Materials and Methods
2.1. Antibodies and reagents
Antibodies anti-FAK, anti-myogenin, anti-p21, anti-Ki67 and
anti-SHP-2 were from Santa Cruz Biotechnology. Anti-phospho-
FAK-Tyr-397 was from Biosource, Protein G plus was from Onco-
gene, and anti-rabbit biotined secondary antibody was from GE
Healthcare. Lipofectamine was from Invitrogen. Dulbecco’s modi-
ﬁed Eagle’s minimal medium (DMEM) and penicillin–streptomycinlsevier B.V. All rights reserved.
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and 35-mm plastic culture dishes were from Corning.2.2. Cell culture
C2C12 cells from adult mouse skeletal muscle (ATCC) were
grown in DMEM supplemented with 10% fetal bovine serum and
1% penicillin–streptomycin under a humidiﬁed atmosphere of 5%
CO2 in air and maintained at low conﬂuence. To induce differenti-
ation, we changed culture medium to 2% horse serum when cells
reached 70% conﬂuence, as previously reported [9].2.3. siRNA synthesis and transfection protocol
siRNA duplex targeted to mouse SHP-2 (siSHP-2) or GFP (siGFP)
were designed and synthesized, as previously reported [13,19].
Cells were transfected with siSHP-2 or siGFP complexed with
lipofectamine.Fig. 1. (A) Immunoblottings of anti-FAK and anti-phosphoFAK antibodies and graph show
cultured in high (HS) and low serum (LS). (B) Immunoblotting and graph representing
activity of anti-SHP-2 immunoprecipitates from C2C12 cells (six experiments). (D) Im
immunoprecipitates from C2C12 cells (ﬁve experiments). *P < 0.05 compared with proli2.4. Western blotting analysis
Equal amounts (30 lg) of cell protein extracts were resolved in
SDS-PAGE. Resolved proteins were eletrophoretically transferred
to nitrocellulose membranes, which were incubated with primary
antibodies targeted to FAK, phospho-FAK, SHP-2, myogenin or p21.
2.5. Immunoprecipitation
Equal amounts (2.5 mg) of cell protein extracts were incubated
overnight at 4 C with 15 ll of anti-FAK antibody. Protein G plus
was added and incubated for 2 h at 4 C. Subsequently, the samples
were centrifuged (20 min, 11 000 rpm, 4 C), boiled with Laemmli
buffer, and resolved using SDS–PAGE. Nitrocellulose membranes
were incubated with anti-SHP-2 antibody.
2.6. Cell imaging
Cells were ﬁxed with methanol at 20 C and analyzed by
phase contrast microscopy.ing the percent changes of phosphoFAK/FAK ratio (ﬁve experiments) in C2C12 cells
the percent changes of SHP-2 in C2C12 cells (four experiments). (C) Phosphatase
munoblotting and average values of the amount of SHP-2 detected in anti-FAK
ferating cells.
Fig. 2. (A) Immunoblotting and graph showing the amount of SHP-2 of C2C12 cells treated with siGFP or siSHP-2, compared to untreated cells (ﬁve experiments). (B)
Immunoblotting and graph showing the percent change in SHP-2 protein expression of C2C12 cells treated with siSHP-2 and cultured in high (HS) and low serum (LS) culture
medium (six experiments). (C) Phosphatase activity of the groups referred in (B). (D) Immunoblottings and graph showing the average changes of pFAK/FAK ratio in the
groups referred in (B). (E) Immunoblottings and graph showing the average changes of pFAK/FAK ratio in C2C12 cells transiently depleted of SHP-2. *P < 0.05 compared to
proliferating cells treated with siGFP.
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The proliferative activity was determined by nuclear cell stain-
ing with anti-Ki-67 antibody. Cells (500) in 10 random ﬁelds of
view at 100 magniﬁcation were counted and expressed as the
average number of cells per ﬁeld of view. Cell differentiation was
assessed through expression of myogenin and by analysis of cell
fusion index calculated as the ratio of the number of nuclei in dif-
ferentiated cells and the total number of nuclei in culture dishes,
according to a method previously described [9].
2.8. Phosphatase activity
The protein–tyrosine phosphatase activities of anti-Shp2 com-
plexes were assayed based on the hydrolysis of pp60-cSrc phos-
phoregulatory peptide [13].Fig. 3. (A) Anti-Ki67 staining of C2C12 cells treated with siGFP and cultured in high seru
low serum medium. (C) Bar graph showing the average values of Ki67 positive C2C12 c
medium (six experiments). (D) Anti-Ki67 staining of C2C12 cells treated with siSHP-2 an
positive C2C12 cells treated with siSHP-2 and cultured in high serum (HS) or low serum
samples of proliferating and differentiating C2C12 cells treated with siGFP or siSHP-2 (p2.9. Statistical analysis
Data are presented as means ± S.E. Differences between mean
values of the densitometric readings were tested using ANOVA
and Bonferroni’s multiple-range test. A value of P < 0.05 indicated
statistical signiﬁcance.
3. Results
We initially examined FAK phosphorylation at Tyr-397 during
the transition from proliferation to early myotube differentiation
of C2C12 cells induced by serum starvation. Phosphorylated FAK
was reduced to 10% soon after the culture medium was switched
from high to low serum, but returned to basal levels after 8 h in
low serum (Fig. 1A) The amount of FAK remained unaltered up
to 24 h after the culture medium switch.m medium. (B) Anti-Ki67 staining of C2C12 cells treated with siGFP and cultured in
ells treated with siGFP and cultured in high serum (HS) or low serum (LS) cultured
d cultured in low serum medium. (E) Bar graph showing the average values of Ki67
cultured medium (ﬁve experiments). (F) Immunoblottings of anti-p21antibody with
ool of three experiments).
Fig. 4. (A) Anti-myogenin immunoblottings of extracts from C2C12 cells cultured in HS or LS and treated with siGFP or siSHP-2. (B) Bar graph showing the average values of
the immunoblottings shown in A (ﬁve experiments). (C–F) Representative examples of proliferating (HS) and differentiating (LS, 48 h) C2C12 cells treated with siGFP or
siSHP-2. (G) Cell fusion index of serum-starved (48 h and 120 h) C2C12 cells treated with siGFP or siSHP-2 (ﬁve experiments). *P < 0.05 compared to HS treated with siGFP;
#P < 0.05 compared to HS treated with siSHP-2.
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liferating and in differentiating C2C12 cells. As shown in Fig. 1B,
the expression of SHP-2 did not change in differentiating compared
to proliferating cells. However, the SHP-2 tyrosine phosphatase
activity was transiently increased, returning to basal levels 4 hours
after the switch to low serum medium (Fig. 1C). Co-immunopre-
cipitation assays were used to examine whether SHP-2 interacts
with FAK. Relatively small amounts of SHP-2 were found in the
anti-FAK immune complex precipitated from proliferating C2C12
cells (Fig. 1D). The amount of SHP-2 precipitated by anti-FAK anti-
body transiently increased upon serum starvation, in parallel with
the increased SHP-2 activity and reduced FAK phosphorylation.
The levels of SHP-2 associated with FAK returned to basal levels
after cells were serum starved for 4 h.
To assess whether SHP-2 regulates the levels of FAK phosphor-
ylation during differentiation, C2C12 cells were depleted of SHP-2
with speciﬁc siRNA. Introduction of siSHP-2, but not siGFP, in pro-
liferating C2C12 cells resulted in marked reduction of SHP-2
(80%) in proliferating cells (Fig. 2A). Depletion of SHP-2 was ob-
served in treated cells up to 8 h after the culture medium was
switched to low serum (Fig 2B). SHP-2 knockdown was shown to
suppress the transient increase of SHP-2 activity in differentiating
C2C12 cells (Fig. 2C) and increased FAK phosphorylation in differ-
entiating, but not in proliferating cells (Fig. 2D). Moreover, in cells
treated with siSHP2 FAK phosphorylation increased progressively
up to 120 h after the culture medium switch to low serum
(Fig. 2E). FAK protein expression remained unchanged in cells trea-
ted with siSHP-2 or siGFP.
Next, we examined the inﬂuence of SHP-2 knockdown on
C2C12 proliferation and differentiation of serum-starved C2C12
cells. Cell proliferation, as assessed by cell nuclei labeling with
anti-Ki67 antibody, was markedly reduced in C2C12 cells treated
with siGFP after the switch to low serum (Fig. 3A–C). SHP-2 knock-
down suppressed the inhibition of proliferation induced by low
serum, but it did not affect basal proliferation of C2C12 cells main-
tained in high serum culture medium (Fig. 3D and E). The expres-
sion of cyclin-dependent kinase inhibitor p21 was examined as a
marker of cell cycle withdrawal in C2C12 cells. As shown in
Fig. 3E, transient depletion of SHP-2 markedly retarded the rise
of p21 induced by low serum culture medium in C2C12 cells.
Myogenin, a marker of cell differentiation, could not be detected
in proliferating C2C12 myoblasts treated with siGFP, but it was ex-
pressed after 24 h in low serum (Fig. 4A and B). Depletion of SHP-2
markedly retarded the rise of myogenin in serum-starved cells.
Cells treated with siSHP-2 were increased in number, but rarely
formed myotubes after the switch of culture medium to low serum
(Fig. 4C–F). The rise of the fusion index into myotubes was mark-
edly attenuated in cells transiently depleted of siSHP-2, indicating
that transient depletion of SHP-2 inhibits the formation of myotu-
bes (Fig. 4G).4. Discussion
During myogenesis of C2C12 cells in vitro, myoblasts are in-
duced to exit from the cell cycle by a decrease in growth factors,
initiate muscle-speciﬁc gene expression, and subsequently fuse
into multinucleated myotubes. Data from previous studies support
a model in which the commitment of C2C12 cells to differentiation
is dependent on a transient inhibition of FAK but, terminal differ-
entiation is critically dependent on FAK activation [4,9,11]. We re-
port here a reciprocal relationship between the levels of FAK
phosphorylation and SHP-2 activity in the control of myogenesis
in C2C12 myoblasts. A rapid and transient FAK dephosphorylation
during myogenesis coincided with enhanced SHP-2 phosphatase
activity and association with FAK while depletion of SHP-2 inducedby siRNA suppressed the transient FAK dephosphorylation. There-
fore, it is reasonable to conclude that the transient FAK dephospho-
rylation that occurs early on during myogenesis in C2C12 cells
depends on the activation of SHP-2.
SHP-2 was shown here to be transiently activated in C2C12
myoblasts after the switch to differentiation condition. Similarly,
basal activity of SHP-2 has been shown to be increased in serum-
starved cardiac myocytes [13]. Moreover, data from previous stud-
ies indicate that SHP-2 is upregulated during myogenesis by a
mechanism dependent on interaction with tyrosyl-phosphorylated
proteins [18]. Interestingly, several proteins are tyrosyl-phosphor-
ylated in differentiating myoblasts. Speciﬁcally, SIRP-1a becomes
tyrosyl-phosphorylated and associates with active SHP-2 in differ-
entiating myoblasts, but it is unclear whether phosphorylation of
SHPS-1a is sufﬁcient to activate SHP-2 and initiate differentiation
of myoblasts [18]. In addition, the mechanism responsible for
SIRP-1a phosphorylation in response to serum starvation also re-
mains to be determined.
The data of this study also show that the transient depletion of
SHP-2 inhibited the expression of p21 and led serum-starved
C2C12 cells to persist proliferating. In addition, the transient deple-
tion of SHP-2 inhibited the expression of myogenin and the forma-
tion of myotubes in C2C12 cells maintained in differentiation
conditions. These data are in line with those of previous studies
indicating that depletion of SHP-2 inhibits myoblasts differentia-
tion into myotubes [17]. The inhibition of myogenesis in cells de-
pleted of SHP-2 was shown here to be associated with the
suppression of the transient FAK dephosphorylation. Similar to
SHP-2 depletion, the suppression of the transient reduction of
FAK phosphorylation induced by overexpression of wild-type
FAK, was previously demonstrated to impair the cell cycle arrest
and the differentiation of myoblasts triggered by serum starvation
[9]. Together, these data support the interpretation that the early
activation of SHP-2 is required to inhibit C2C12 proliferation and
to commence myogenesis via dephosphorylation of FAK. Moreover,
we demonstrated here that the inhibition of p21 and myogenin
expression lasted for at least 4 days in cells transiently depleted
of SHP-2 maintained in low serum culture medium. Interestingly,
high levels of FAK phosphorylation were demonstrated in these
cells. These data may suggest that an increased activity of FAK,
without the intervening transient reduction that follows the switch
of culture medium to low serum, may induce these cells to main-
tain a high proliferative activity and impairment of myogenesis.
However, further studies are needed to conﬁrm this hypothesis.
In summary, the present study demonstrates that activation of
SHP-2 is required for a transient downregulation of FAK which is
critical to inhibit proliferation and to commence differentiation
of C2C12 myoblasts in response to serum starvation.Acknowledgements
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